|Bid||17.50 x 200|
|Ask||17.51 x 100|
|Day's range||16.59 - 17.58|
|52-week range||4.08 - 17.58|
|PE ratio (TTM)||N/A|
|Earnings date||1 Feb 2017 - 6 Feb 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.33|
Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced a collaboration with the Carbone Cancer Center at the University of Wisconsin, through Immunomedics entering an agreement with The Prostate Cancer Clinical Trials Consortium (PCCTC), to investigate Immunomedics’ lead antibody-drug conjugate (ADC) product candidate, sacituzumab govitecan, in an investigator-sponsored Phase 2 trial in patients with advanced castration-resistant prostate cancer (CRPC). “The therapeutic landscape for men with CRPC has become limited.
Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time in San Francisco, CA. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases.
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 97 cents. Losses, adjusted for non-recurring costs, were 16 cents per share. The results fell short of Wall Street ...
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: IMMU) under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, which is expressed in several solid tumors including cancers of the breast, lung and bladder.